Michael B. Atkins

Michael B. Atkins serves as the Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center, where he plays a pivotal role in advancing cancer research and treatment. His dedication and significant contributions to the field have earned him the honor of being inducted as a Fellow of the Academy of Immuno-Oncology. This prestigious recognition underscores his commitment to the development and implementation of innovative cancer therapies. Atkins holds the esteemed Dr. Scholl Chair in Medical Oncology, a testament to his leadership and expertise in the field. His work primarily focuses on the burgeoning field of immunotherapy, where he has achieved remarkable clinical results. Through his efforts, immunotherapy has emerged as a promising approach in the quest to make cancer a curable disease. His research is particularly centered on identifying biomarkers that can guide targeted therapy, a critical aspect of personalized medicine. In addition to his research, Atkins is deeply involved in addressing the challenges associated with cancer treatment. He is known for his work on understanding resistance mechanisms that often limit the effectiveness of therapies. Furthermore, he is committed to managing the side effects of treatment, ensuring that patients receive the most effective care with minimal discomfort. His efforts also extend to optimizing the duration of treatment, balancing efficacy with quality of life for patients. Atkins' contributions are a reflection of the exceptional caliber of faculty at Georgetown Lombardi Comprehensive Cancer Center. His work not only advances the scientific understanding of cancer but also translates into tangible improvements in patient outcomes. His dedication to the field of cancer research and his innovative approach to treatment continue to inspire both his colleagues and the broader medical community. Through his leadership and research, Michael B. Atkins exemplifies the mission of Georgetown University to push the boundaries of medical science and improve the lives of those affected by cancer. His ongoing efforts in the field of immuno-oncology are paving the way for new treatment paradigms and offering hope to countless patients and their families.